CV Events in Emetogenic Chemotherapy

Observational Study of Delayed Nausea and Vomiting

NCT00696280 ·Status: COMPLETED

Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting

NCT04592198 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety Evaluation of Carbamazepine for Prevention of Chemotherapy-induced Nausea and Vomiting

NCT01581918 ·Status: UNKNOWN ·Phase: PHASE2

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

NCT05841849 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)

NCT04817189 ·Status: COMPLETED ·Phase: PHASE4

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

NCT01432015 ·Status: COMPLETED ·Phase: PHASE4

Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC

NCT05199818 ·Status: UNKNOWN ·Phase: PHASE3

Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.

NCT01913990 ·Status: UNKNOWN ·Phase: PHASE4

Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy

NCT01402024 ·Status: COMPLETED ·Phase: PHASE3

Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone

NCT05872893 ·Status: UNKNOWN ·Phase: PHASE3

Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

NCT06065722 ·Status: UNKNOWN ·Phase: PHASE2

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)

NCT00337727 ·Status: COMPLETED ·Phase: PHASE3

Incidence and Patterns of Nausea/Vomiting With Combined Chemotherapy and Radiation

NCT00716157 ·Status: COMPLETED

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

NCT00092196 ·Status: COMPLETED ·Phase: PHASE3

Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.

NCT05755659 ·Status: UNKNOWN ·Phase: NA

Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin

NCT01012336 ·Status: COMPLETED ·Phase: PHASE2

Drugs to Reduce the Side Effects of Chemotherapy

NCT00003213 ·Status: COMPLETED ·Phase: PHASE3

Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

NCT02116530 ·Status: COMPLETED ·Phase: PHASE3

Predict CHimio-or Radiation-induced NAusea and Vomiting in Children/adolescents Treated for Cancer

NCT06869005 ·Status: NOT_YET_RECRUITING

Prevention of Unmitigated Chemotherapy-induced Emesis

NCT03996863 ·Status: WITHDRAWN ·Phase: NA

Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy

NCT00104403 ·Status: COMPLETED ·Phase: PHASE2

Emend for Multiple-day Emetogenic Chemotherapy

NCT00711555 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea

NCT04937309 ·Status: UNKNOWN ·Phase: NA

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

NCT00092183 ·Status: COMPLETED ·Phase: PHASE4

the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

NCT04430361 ·Status: UNKNOWN ·Phase: PHASE2